RxDoctor Payments Data

Edward Salerno, MD

Pulmonary Disease · Naples, FLNPI 1912970344

Payments from drug & device makers

$154,043in general payments, 2019–2025

Across 1,050 payments — averaging $146.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$126K
  • Bayer$5K
  • AstraZeneca$5K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Inspire Medical Systems, Inc.$2K
  • Boehringer Ingelheim$2K
  • plus $12K from 44 others

What the payments were for

  • Speaking & faculty fees$127,53583%
  • Travel & lodging$1,9321%
  • Food & beverage$24,35916%
  • Education$2170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$154,043 in reported general payments places this provider in the 85th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$488,688
Medicare patients
1,996
Services billed
5,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter538$538,873
GlassiaAlpha-1-Proteinase Inhibitor27$329,296
AdempasRiociguat15$186,741
Aralast NpAlpha-1-Proteinase Inhibitor14$164,553
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr131$126,134
Breo ElliptaFluticasone/Vilanterol143$89,898
Breztri AerosphereBudesonide/Glycopyr/Formoterol71$76,932
Spiriva RespimatTiotropium Bromide69$55,052
Ambrisentan20$50,446
XareltoRivaroxaban33$48,097
Stiolto RespimatTiotropium Br/Olodaterol Hcl45$40,078
MounjaroTirzepatide33$38,089
EliquisApixaban24$21,799
Arnuity ElliptaFluticasone Furoate68$19,239
SymbicortBudesonide/Formoterol Fumarate41$16,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$126,344$774,144880 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$2,180$329,29627 claims
BayerAdempas$5,371$186,74115 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$4,818$103,326124 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$1,629$95,129114 claims
Johnson & JohnsonXarelto$401$48,09733 claims
Lilly USA, LLCMounjaro$14$38,08933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →